Stock Track | Y-mAbs Stock Plunges 7% as Q3 Earnings Disappoint on Higher Costs

Stock Track11-08

Shares of Y-mAbs Therapeutics, Inc. (YMAB) plummeted 7.33% in pre-market trading on Wednesday, November 8, 2024, after the biopharmaceutical company reported disappointing third-quarter financial results, largely due to higher-than-expected operating expenses.

Y-mAbs reported total net revenues of $18.5 million for the third quarter of 2024, a 10% decline from $20.5 million in the same period last year. The company's lead product, DANYELZA, generated net product revenues of $18.5 million, with $15.3 million coming from the U.S. market and $3.1 million from ex-U.S. markets.

However, Y-mAbs' operating costs and expenses for the quarter rose to $27 million, compared to $28.2 million a year ago. The increase was primarily driven by higher selling, general, and administrative expenses, which jumped to $13.6 million from $10.2 million in the third quarter of 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment